Just to let you know that the report is ready on their website.
Here’s what it says :
The Aderans Group is also promoting R&D in hair regeneration, whereby hair is regenerated at the cell-tissue level, at the Aderans Research Institute in the US, with a view to establishing a timeframe for commercialization in 2009.
I scanned it very quickly but I didn’t read anything about trials. I wonder how they can still target 2009, because we are only 1.5 years away from 2009. Either, they are lying or they know something we don’t…
They are just talking about a “timeframe” for commercialization in 2009, not actual commercialization.
Keep in mind Aderans owns Bosley, which has an agreement with Intercytex. Notice the wording – it could be that they are basing their commercialization plan on data from Intercytex, not Aderans Research Institute. This would roughly fit ICX-TRC’s timeline, with Phase II entirely complete in 2009.
All the best,
BB
» Just to let you know that the report is ready on their website.
»
» Here’s what it says :
»
» The Aderans Group is also promoting R&D in hair regeneration, whereby hair
» is regenerated at the cell-tissue level, at the Aderans Research Institute
» in the US, with a view to establishing a timeframe for
» commercialization in 2009.
»
»
» I scanned it very quickly but I didn’t read anything about trials. I
» wonder how they can still target 2009, because we are only 1.5 years away
» from 2009. Either, they are lying or they know something we don’t…
» Just to let you know that the report is ready on their website.
»
» Here’s what it says :
»
» The Aderans Group is also promoting R&D in hair regeneration, whereby hair
» is regenerated at the cell-tissue level, at the Aderans Research Institute
» in the US, with a view to establishing a timeframe for
» commercialization in 2009.
yea, maybe in 2009 is when they will START trying to establish a timeline once we are in 2009, lol.
if ICX posted this then it’d be different. but we already know they are saying no sooner than 2010.
PAGE 7:
Turning to the hair-transplant business, which is growing in North America, we will invest
our management resources efficiently—to expand our network, for example—and develop our
business aggressively. In parallel with our efforts to expand Bosley’s market share and further
enhance its profitability, we have concluded a basic agreement with Leavitt Management, Inc.,
allowing us to take over its hair-transplant business, run by Medical Hair Restoration, Inc.,
which ranks second in the U.S. hair-transplant industry. We also plan to advance the business
into other overseas markets. R&D in hair-regeneration technology is proceeding according to
schedule, and we expect to release practical data concerning commercialization in 2009. PAGE 11
At the same time, we are conducting research and development relating to hairregeneration
technology at Aderans Research Institute, Inc.—in the U.S., with a view to establishing
a timeframe for commercialization in 2009. PAGE 19
The Aderans Group is also promoting R&D in hair regeneration, whereby hair is regenerated at the
cell-tissue level, at the Aderans Research Institute in the U.S., with a view to establishing a timeframe for
commercialization in 2009. Cell regeneration entails removing tissue from underneath the hair roots and
extracting the hair follicle cells. These cells are then cultured until they multiply, and injected back into
balding areas, enabling hair regrowth from a greater number of hair-forming cells. PAGE 31
SGA expenses increased marginally by 0.1% year on year to ¥29,823 million. The main
components were advertising expenses, which edged down 0.5% to ¥8,927 million and personnel
expenses, which decreased 2.6% to ¥9,203 million. Research and development expenses totaled
1,692 million ($14 million), reflecting a 62.1% year on year increase in the cost of research into
hair-regeneration technology. PAGE 37
Aderans’ R&D activities are currently directed toward the pursuit of hair-regeneration techniques.
The Company cannot guarantee that its efforts to develop such techniques will be successful, or
that such efforts, if they were successful, would generate profits in the short term. In addition, it
is difficult to predict with accuracy at the present time what the scale of demand might be for
hair-regeneration techniques, should such methods be marketable at some point in the future.
» PAGE 7:
» Turning to the hair-transplant business, which is growing in North
» America, we will invest
» our management resources efficiently—to expand our network, for
» example—and develop our
» business aggressively. In parallel with our efforts to expand Bosley’s
» market share and further
» enhance its profitability, we have concluded a basic agreement with
» Leavitt Management, Inc.,
» allowing us to take over its hair-transplant business, run by Medical Hair
» Restoration, Inc.,
» which ranks second in the U.S. hair-transplant industry. We also plan to
» advance the business
» into other overseas markets. R&D in hair-regeneration technology is
» proceeding according to
» schedule, and we expect to release practical data concerning
» commercialization in 2009.
» PAGE 11
» At the same time, we are conducting research and development relating to
» hairregeneration
» technology at Aderans Research Institute, Inc.—in the U.S., with a view
» to establishing
» a timeframe for commercialization in 2009.
» PAGE 19
» The Aderans Group is also promoting R&D in hair regeneration, whereby hair
» is regenerated at the
» cell-tissue level, at the Aderans Research Institute in the U.S., with
» a view to establishing a timeframe for
» commercialization in 2009. Cell regeneration entails removing tissue
» from underneath the hair roots and
» extracting the hair follicle cells. These cells are then cultured until
» they multiply, and injected back into
» balding areas, enabling hair regrowth from a greater number of
» hair-forming cells.
» PAGE 31
» SGA expenses increased marginally by 0.1% year on year to ¥29,823 million.
» The main
» components were advertising expenses, which edged down 0.5% to ¥8,927
» million and personnel
» expenses, which decreased 2.6% to ¥9,203 million. Research and development
» expenses totaled
» 1,692 million ($14 million), reflecting a 62.1% year on year increase
» in the cost of research into
» hair-regeneration technology.
» PAGE 37
» Aderans’ R&D activities are currently directed toward the pursuit of
» hair-regeneration techniques.
» The Company cannot guarantee that its efforts to develop such techniques
» will be successful, or
» that such efforts, if they were successful, would generate profits in the
» short term. In addition, it
» is difficult to predict with accuracy at the present time what the scale
» of demand might be for
» hair-regeneration techniques, should such methods be marketable at some
» point in the future.
Yeah, it could be read two ways:
The way we would like it to be is that they create a timeframe that has commercialization in 2009.
Or, that they release a timeframe in 2009 regarding commercialization.
»
» Yeah, it could be read two ways:
» 1. The way we would like it to be is that they create a timeframe that
» has commercialization in 2009.
» 2. Or, that they release a timeframe in 2009 regarding commercialization.
» I scanned it very quickly but I didn’t read anything about trials. I
» wonder how they can still target 2009, because we are only 1.5 years away
» from 2009. Either, they are lying or they know something we don’t…
Oh, I just read it. They are not saying they will have it available by 2009.
“R&D in hair-regeneration technology is proceeding according to
schedule, and we expect to release practical data concerning commercialization in 2009.”
So they will release some data concerning commercialization. That is very different from having it ready by then.
“with a view to establishing a timeframe for commercialization in 2009.”
Once again, this does not say they will have it ready by 2009. It says that in 2009, they hope to know the time-frame. IOW, a minimum of 2012 before their protocol is ready for market.
» Once again, this does not say they will have it ready by 2009. It says
» that in 2009, they hope to know the time-frame. IOW, a minimum of 2012
» before their protocol is ready for market.
That sounds about right. (But on the other hand, Ken Washenik did say in a recent interview with Donny Deutsch that it was gonna be available in 2009/2010.)
» Oh, I just read it. They are not saying they will have it available by
» 2009.
They’re not saying that it WON’T be available by 2009 either. It is just possible that they don’t know themselves when it’s gonna be available.
FACT #1: ADERANS RESEARCH INC (Ken Washenik), INTERCYTEX (Paul Kemp), and BOSLEY (which will do the HM procedures) are ALL “owned” by ADERANS.
FACT #2: Aderans is basing it’s “timeframe for commercialization” on Intercytex data, which will end Phase II in 2008-09.
FACT #3: Ken Washenik is saying 2009/2010 because he knows exactly what Intercytex, Bosley, and Aderans are doing. He knows Intercytex will be providing first-round HM in 2010 and Aderans Research Inc. will be providing second-round HM in 2012 or so.
We should be glad Aderans is expecting a “timeframe for commericalization” in 2009, because it means Intercytex is progressing nicely on Phase II trials.
Why doesn’t anyone get this???
All the best,
BB
» » Once again, this does not say they will have it ready by 2009. It says
» » that in 2009, they hope to know the time-frame. IOW, a minimum of 2012
» » before their protocol is ready for market.
»
» That sounds about right. (But on the other hand, Ken Washenik did say in a
» recent interview with Donny Deutsch that it was gonna be available in
» 2009/2010.)
»
» » Oh, I just read it. They are not saying they will have it available by
» » 2009.
»
» They’re not saying that it WON’T be available by 2009 either. It is just
» possible that they don’t know themselves when it’s gonna be available.
» Hey,
»
» FACT #1: ADERANS RESEARCH INC (Ken Washenik), INTERCYTEX (Paul Kemp), and
» BOSLEY (which will do the HM procedures) are ALL “owned” by ADERANS.
»
» FACT #2: Aderans is basing it’s “timeframe for commercialization” on
» Intercytex data, which will end Phase II in 2008-09.
»
» FACT #3: Ken Washenik is saying 2009/2010 because he knows exactly what
» Intercytex, Bosley, and Aderans are doing. He knows Intercytex will be
» providing first-round HM in 2010 and Aderans Research Inc. will be
» providing second-round HM in 2012 or so.
»
» We should be glad Aderans is expecting a “timeframe for commericalization”
» in 2009, because it means Intercytex is progressing nicely on Phase II
» trials.
»
» Why doesn’t anyone get this???
»
» All the best,
» BB
»
Why do you think that Anderans owns all these companies? You are the first person to mention this in any posts I have ever read here. Did you invent this, or do you have any proof of this partnership? Please supply documentation
Okay, so this is what we know: Aderans, a big Japanese wig-maker, owns Aderans Research Inc., which is doing work on hair multiplication. Recall that Aderans Research Inc. is headed by Ken Washenik. Aderans also owns Bosley, which is America’s biggest hair transplant company. All of this is well-documented, just read Aderans’ annual report.
This is what we also know, at least since 2004-05: Bosley, which is owned by Aderans, has an exclusive agreement with Intercytex. Basically Intercytex has agreed to give Bosley first rights on Intercytex’s hair multiplication procedure known as ICX-TRC. This is documented in numerous news stories from 2004. Here’s a typical article: http://www.encyclopedia.com/doc/1G1-116094556.html
Now isn’t this looking like a hair multiplication orgy? But it now everything begins to make sense. For example, now it makes sense why Aderans Research Inc has released basically NO new information since 2004-05: so as not to take funding/investors away from Intercytex. Now it makes sense why Ken Washenik says “2009-2010” even though Aderans Research Inc is only in Phase I trials: Intercytex will have small-scale commericalization by then. And now it makes sense why Aderans’ annual report is announcing commercialization plans in “2009”: this is when Intercytex’s Phase II trials on efficacy will be complete.
IT is all connected, my friends… Aderans wants to minimize its risk, so it will be using HM technology from BOTH Aderans Research Inc and Intercytex, with Aderans Research Inc providing a second-round HM procedure (say, in 2012 or later) after Intecytex’s first-round procedure (say, in 2010).
All the best,
BB
» Why do you think that Anderans owns all these companies? You are the
» first person to mention this in any posts I have ever read here. Did you
» invent this, or do you have any proof of this partnership? Please supply
» documentation
» Hey,
»
» FACT #1: ADERANS RESEARCH INC (Ken Washenik), INTERCYTEX (Paul Kemp), and
» BOSLEY (which will do the HM procedures) are ALL “owned” by ADERANS.
BostonBaldy, you’re stretching it a lot when you say that ICX is “owned” by Aderans. Far from it, Intercytex is definitely not owned or controlled by Aderans. They just have an agreement that Bosley (which Aderans really does own) will have first, exclusive rights to provide ICX-TRC in its US clinics.
Intercytex and Aderans have completely separate corporate structures and completely different owners and managers. Aderans is a Japanese company with no ties to Intercytex (a UK company), other than that one agreement.
Other than that, what you wrote about Washenik knowing all about Intercytex’s plans does make sense. Why wouldn’t he know? He’s about as much of an insider as you can get.
That’s why I put “owned” in quotes… but I really suspect that Aderans knows what Intercytex is doing. And Ken Washenik is no fool, maybe overly optimistic, but hey, he has pretty thin hair, eh?
» » Hey,
» »
» » FACT #1: ADERANS RESEARCH INC (Ken Washenik), INTERCYTEX (Paul Kemp),
» and
» » BOSLEY (which will do the HM procedures) are ALL “owned” by ADERANS.
»
» BostonBaldy, you’re stretching it a lot when you say that ICX is “owned”
» by Aderans. Far from it, Intercytex is definitely not owned or
» controlled by Aderans. They just have an agreement that Bosley (which
» Aderans really does own) will have first, exclusive rights to provide
» ICX-TRC in its US clinics.
»
» Intercytex and Aderans have completely separate corporate structures and
» completely different owners and managers. Aderans is a Japanese company
» with no ties to Intercytex (a UK company), other than that one agreement.
»
» Other than that, what you wrote about Washenik knowing all about
» Intercytex’s plans does make sense. Why wouldn’t he know? He’s about
» as much of an insider as you can get.
» That’s why I put “owned” in quotes… but I really suspect that Aderans
» knows what Intercytex is doing. And Ken Washenik is no fool, maybe overly
» optimistic, but hey, he has pretty thin hair, eh?
»
» » » Hey,
» » »
» » » FACT #1: ADERANS RESEARCH INC (Ken Washenik), INTERCYTEX (Paul Kemp),
» » and
» » » BOSLEY (which will do the HM procedures) are ALL “owned” by ADERANS.
» »
» » BostonBaldy, you’re stretching it a lot when you say that ICX is
» “owned”
» » by Aderans. Far from it, Intercytex is definitely not owned or
» » controlled by Aderans. They just have an agreement that Bosley (which
» » Aderans really does own) will have first, exclusive rights to provide
» » ICX-TRC in its US clinics.
» »
» » Intercytex and Aderans have completely separate corporate structures
» and
» » completely different owners and managers. Aderans is a Japanese
» company
» » with no ties to Intercytex (a UK company), other than that one
» agreement.
» »
» » Other than that, what you wrote about Washenik knowing all about
» » Intercytex’s plans does make sense. Why wouldn’t he know? He’s
» about
» » as much of an insider as you can get.
Yes, in a perfect world these two companies would share information and technology in order to arrive at a viable treatment as soon as possible. They would also be able to avert set backs by learning from each others mistakes.
That being said, you imply that these two companies are not racing each other to the market. It almost sounds like Aderans is “happy” to secede the market introduction to ICX which doesn’t sound right to me.
Let’s hope BB you are pointed in the right direction. I am all for a swifter conclusion to this life-long dilemma.
BTW - Were those new phase 1(?) pictures taken off of the internet once they were discovered.
I don’t think they’re sharing info in extreme detail, but they are working on different procedures towards HM so in that sense they aren’t competing. But in some ways i think Aderans Research Inc is allowing Intercytex to go into the market first, b/c they have a viable product sooner. But Aderans Research won’t care, b/c they are owned by Aderans. And Ken Washenik will just start doing ICX-TRC type research.
Those phase I pics were changed to a new file called “cell02” soon after cockyninja posted them on this website. At the time I suspected somebody from Intercytex saw people commenting on the photos and got rid of it… but then we found out they just changed the name. Was it due to this site? Who knows…?
all the best,
BB
»
» Yes, in a perfect world these two companies would share information and
» technology in order to arrive at a viable treatment as soon as possible.
» They would also be able to avert set backs by learning from each others
» mistakes.
»
» That being said, you imply that these two companies are not racing each
» other to the market. It almost sounds like Aderans is “happy” to secede
» the market introduction to ICX which doesn’t sound right to me.
»
» Let’s hope BB you are pointed in the right direction. I am all for a
» swifter conclusion to this life-long dilemma.
»
» BTW - Were those new phase 1(?) pictures taken off of the internet once
» they were discovered.
You forgot to mention that Aderans owns the TWO largest HT companies in the U.S. They have an enormous amount of infrastructure and a virtual monopoly on the procedure.
This is an advertising site for paid
advertisers to showcase successful hair restoration results only. It is not the
mandate of this site to engage in the discussion of failed, unsuccessful
procedures, lawsuits, litigations, refunds or complaint cases. Surgical hair
restoration procedures carry risks. Please do thorough research, consult your
own physician and investigate a doctor's background carefully before making a
decision. By proceeding to use our site, you agree to abide by our Terms of Use & Privacy Policy at http://hairsite.com/terms-of-use/ where you can also find a list of HairSite's sponsoring physicians.
